Prime Medicine reports Q4 net loss $39.3M, FY2022 net loss $121.8M; nominates PM359 for CGD

Prime Medicine, Inc.

Q4 2022 net loss $39.3M improved from $62.9M in Q4 2021; FY2022 net loss $121.8M vs $165.4M prior year.
R&D expenses $29.1M in Q4 and $86.7M for FY2022; G&A $9.6M and $29.8M, respectively.
Cash, short-term investments $293.9M as of Dec 31, 2022, up from $269.6M year-end 2021, boosted by $180.2M IPO net proceeds.
Nominated PM359 as first development candidate for chronic granulomatous disease (CGD); IND-enabling studies planned for 2023.
Preclinical proof-of-concept data for FRDA, CF, and Wilson's disease; first IND filing expected as early as 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Prime Medicine, Inc. reported the year ended December 31, 2022 results: net income Net loss was $121.8 million for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Net income: Net loss was $121.8 million for the year ended December 31, 2022
Result: reported results

Exact text from the filing

Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Prime Medicine, Inc. reported the fourth quarter of 2022 results: net income Net loss was $39.3 million for the fourth quarter of 2022.

Period: the fourth quarter of 2022
Net income: Net loss was $39.3 million for the fourth quarter of 2022
Result: reported results

Exact text from the filing

Net loss was $39.3 million for the fourth quarter of 2022 and $121.8 million for the year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

Prime Medicine, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-066791

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.